Invokana Decreases Autoimmune Risk Save
In September, the FDA issued warnings that the dipeptidyl peptidase-4 (DPP4) inihibitor Invokana may cause a dose-dependant increased risk of bone fractures. This was based on a review of nine clinical trials. Such fractures could occur as early as 12 weeks after initiation and with minor traumatic provocation.
Invokana is again in the spotlight as Kim and coworkers published their analyses of DPP4 inhibitors and the risk of autoimmune disease.
Using insurance claims data they analyzed 73 928 patients with T2DM starting DPP4i combination therapy and 163 062 starting non-DPP4i combination therapy. were selected. Risks of incident RA and other autoimmune diseases were lower in the DPP4i group (HR of 0.66; 95% CI 0.44 to 0.99) for RA, 0.73; 95CI 0.51 to 1.03) for other autoimmune diseases.
These data auggest a new alternative pharmacological pathways for prevention or treatment of RA and autoimmune disease.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.